NeuroSense Investor Relations

NASDAQNRSN

Investor Relations

About Us

Pipeline

Media

Investor RelationsClick here to open mobile navigation

Recent News

Investor Alerts

Nov 21, 2024

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce...

Oct 28, 2024

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense...

Oct 24, 2024

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced...

Latest Events

No events to display

Investor Presentation

Download PDF

Board Diversity Matrix

Download PDF

Investor Relations

Home

Research

About

Publications